ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1087

Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus

Zoe Reed1, Catriona Wagner2, Xana Howard1, Alexandre Cammarata-Mouchtouris1, Study Team ALE06 Clinical1, Wade DeJager3 and Judith James1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Santa Cruz, CA, 3Oklahoma Medical Research Foundation, Oklahoma City

Meeting: ACR Convergence 2025

Keywords: Disparities, Epidemiology, Mortality, socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1055–1087) Healthcare Disparities in Rheumatology Posters

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with considerable clinical and molecular heterogeneity. Significant disparities exist in SLE, with minority populations experiencing higher prevalence, increased disease severity, and earlier mortality. Recent studies suggest that adverse social determinants of health may contribute to these disparities. This study evaluated the association between neighborhood-level social vulnerability, measured by the Social Vulnerability Index (SVI), and disease severity, clinical manifestations, and early mortality among female SLE patients in the Lupus Family Registry and Repository (LFRR).

Methods: The LFRR is a large, cross-sectional cohort of SLE patients and their unaffected family members. Patients met ACR 1997 classification criteria for SLE, were female, and had available residential addresses for geocoding (n=3,033). Of those patients, 1,091 were deceased prior to 2024 and included in the early mortality analysis. Disease severity was assessed using the Montgomery Lupus Severity Index (LSI; high severity defined as LSI >7). SVI percentiles (range 0-1) were categorized as high (percentile >0.50) or low (≤ 0.50) vulnerability. Early mortality was defined as death before the average age of death in the US population from 1999-2020, stratified by sex and race. Descriptive statistics and separate logistic regression models were used to evaluate associations with SVI factors, LSI, ACR criteria, and lupus nephritis (LN).

Results: Consistent with previous studies, we observed significant racial differences in disease severity, and clinical manifestations along with higher percentages of early mortality (Table 1 and Figure 1). In univariate analyses, high SVI was associated with increased odds of certain ACR criteria and LSI (Figure 1A). However, these associations were no longer statistically significant after adjusting for race (Figure 1B). Racial differences in disease severity and organ involvement persisted even after accounting for SVI (Figure 1). Patients who died early had significantly higher SVI scores for low economic and household instability factors, indicating greater social vulnerability (Figure 2). Notably, these factors remained significantly associated with early mortality following adjustment for race, sex and high LSI (Figure 2).

Conclusion: In the LFRR, neighborhood-level social vulnerability was not associated with SLE severity or organ involvement after accounting for race. Persistent racial disparities in SLE severity and manifestations suggest that factors beyond area-level vulnerability, including genetic, epigenetic, and individual-level environmental exposures, may play a more substantial role. Social vulnerability, particularly low economic and household instability factors, was significantly associated with early mortality.

Supporting image 1Table 1: Demographic and clinical characteristics

Supporting image 2Figure 1: Associations of social vulnerability index and self-reported race with SLE disease severity and clinical manifestations. (A) Univariate and (B) multivariate logistic regression models for associations with different clinical characteristics. The multivariate model incorporates self-reported race categories and low vs high SVI.

Supporting image 3Figure 2: Associations of social vulnerability index with early mortality in SLE; multivariate logistic regression models for associations with different SVI factors. The multivariate model incorporates self-reported race categories, sex, high LSI, and low vs high SVI.


Disclosures: Z. Reed: None; C. Wagner: None; X. Howard: None; A. Cammarata-Mouchtouris: None; S. ALE06 Clinical: None; W. DeJager: None; J. James: GlaxoSmithKlein(GSK), 2, Progentec, 5.

To cite this abstract in AMA style:

Reed Z, Wagner C, Howard X, Cammarata-Mouchtouris A, ALE06 Clinical S, DeJager W, James J. Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/impact-of-neighborhood-level-social-vulnerability-on-disease-severity-clinical-manifestations-and-early-mortality-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-neighborhood-level-social-vulnerability-on-disease-severity-clinical-manifestations-and-early-mortality-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology